“…Related to these findings, the NE reuptake inhibitor atomoxetine is the first non-stimulant medication that is FDA-approved for treating ADHD ( Bouret and Sara, 2004 ; Bymaster et al, 2002 ; Newman et al, 2008 ). Disruption of noradrenergic signaling is also associated with anxiety, addiction, and responses to stress and trauma, and drugs that modulate noradrenergic signaling have been used in the treatment of post-traumatic stress disorder (PTSD), major depressive disorder (MDD), anxiety, and opioid withdrawal ( Morris et al, 2020 ; Dell’Osso et al, 2011 ; Weinshenker and Schroeder, 2007 ; Berridge and Waterhouse, 2003 ; Urits et al, 2020 ; Paiva et al, 2021 ). Given the wide range of functions that are modulated by the LC-NE system, an improved understanding of the gene expression landscape of the LC and the surrounding region and delineating the molecular profile of LC-NE neurons in the human brain could facilitate the ability to target these neurons for disease prevention or manipulate their function for treatment in a variety of disorders.…”